Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Levin Resigns Unexpectedly, Street Grills Teva’s Chairman On Viability Of Corporate Governance

This article was originally published in The Pink Sheet Daily

Executive Summary

Chairman Philip Frost cited “slight differences” with Teva’s board as the reason that Jeremy Levin resigned. Analysts on a same day call grilled the chairman on Teva’s practice to deny corporate executives a seat on its board, and on the resulting misalignment of board and management objectives.

You may also be interested in...



Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?

Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.

Teva In Transition: Generics, Specialty And ‘The Space Between’

In an interview, President of Global R&D Michael Hayden talked about integrating Allergan generics, Teva’s late-stage specialty pipeline and its 17 new therapeutic entities, medicines that bridge generics and specialty medicine.

Emerging Markets Earnings Roundup: Bayer, Novo Nordisk, Teva (Part 7)

Newer drugs at Bayer helped the bottom line in the third quarter while the world’s top insulin maker Novo Nordisk missed expectations, but held out emerging markets as a bright spot. Teva tussled with analysts on the surprise exit of Jeremy Levin and said that many of the plans during his brief tenure were driven by the board and remain in place.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel